<DOC>
	<DOCNO>NCT01231997</DOCNO>
	<brief_summary>This study design assess effect renal impairment pharmacokinetics , safety tolerability udenafil subject renal impairment compare healthy subject .</brief_summary>
	<brief_title>Clinical Study Investigate Safety Pharmacokinetics Udenafil Tablet Renal Impaired Male Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Adult male age 19 64 year screen . Subjects body weight ≥ 55 kg within ±30 % ideal body weight : Ideal body weight = ( height [ cm ] 100 ) x0.9 . Subjects receive understood completely information regard current study give write informed consent voluntarily participate study follow instruction specify protocol . Subjects test result QTc &gt; 430 m nonsinus cardiac rhythm ECG analysis . Subjects hypotension hypertension . Subjects drunken habitually ( exceed 21 units/week , 1 unit = 10 g pure alcohol ) unable abstain drinking study period 2 day prior first administration investigational product study . Subjects deem ineligible investigator base reason , include abnormal laboratory value disease .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Udenafil</keyword>
	<keyword>DA-8159</keyword>
	<keyword>renal impairment</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>